2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report

[1]  J. Lazarus,et al.  Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. , 2020, Transplantation proceedings.

[2]  M. Cabana,et al.  Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. , 2020, JAMA.

[3]  Ming‐Lung Yu,et al.  Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection. , 2020, Kidney international.

[4]  Ming‐Lung Yu,et al.  Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients. , 2020, Kidney international.

[5]  G. Cooke,et al.  Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis. , 2019, The Lancet. Global health.

[6]  David L. Thomas.  Global Elimination of Chronic Hepatitis. , 2019, The New England journal of medicine.

[7]  B. C. Kwan,et al.  Clinical practice guidelines for the provision of renal service in Hong Kong: Accreditation of Renal Unit , 2019, Nephrology.

[8]  Haibo Sun,et al.  Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD , 2019, Scientific Reports.

[9]  Myeong Jun Song,et al.  Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis , 2019, Gut and liver.

[10]  R. Aggarwal,et al.  Hepatitis C virus infection and chronic renal disease: A review , 2018, Indian Journal of Gastroenterology.

[11]  D. Fliser,et al.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease , 2019, Nephrology and Dialysis.

[12]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[13]  P. Angus,et al.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection , 2018, Hepatology.

[14]  J. Lazarus,et al.  The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations , 2018, Seminars in Liver Disease.

[15]  F. Suzuki,et al.  Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan , 2018, Hepatology International.

[16]  R. Cook,et al.  Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD , 2017, Hepatology.

[17]  F. Sato,et al.  Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus‐infected patients with renal impairment , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  K. Chayama,et al.  Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan , 2017, Journal of Gastroenterology.

[19]  J. M. Freiman,et al.  Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection , 2016, Annals of Internal Medicine.

[20]  T. Ishikawa,et al.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis , 2016, Journal of Gastroenterology.

[21]  F. Sato,et al.  Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C , 2016, Journal of Gastroenterology.

[22]  V. Jha,et al.  Hemodialysis in Asia , 2015, Kidney Diseases.

[23]  M. Stepanova,et al.  A meta‐analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection , 2015, Journal of viral hepatitis.

[24]  P. Messa,et al.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis , 2015, Digestive Diseases and Sciences.

[25]  K. Kalantar-Zadeh,et al.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans , 2015, Hepatology.

[26]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[27]  J. Pawlotsky,et al.  Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[28]  Shang-Jyh Hwang,et al.  Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis , 2014, PloS one.

[29]  Nai-Wan Hsiao,et al.  Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients , 2014, Hepatology.

[30]  Yu-Chieh Su,et al.  Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan , 2013, BMC Nephrology.

[31]  L. Rostaing,et al.  Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[32]  Tao Wang,et al.  Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  A. Macleod.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.

[34]  B. Takkouche,et al.  The impact of hepatitis C virus infection on survival in dialysis patients: meta‐analysis of observational studies , 2007, Journal of viral hepatitis.

[35]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[36]  C. Dolea,et al.  World Health Organization , 1949, International Organization.